Article written by Newcastle MEP Jude Kirton-Darling after she met with EASL Scientific Committee member Dr Helen Louise Reeves, other NE hepatologists and EASL EU Director of Public Affairs, Fiona Godfrey in Newcastle, UK, recently.
Now 3331 members from 103 countries
EASL Clinical School of Hepatology Course 22: Cholestatic Liver Disease
Venue and dates
May 8-9, 2014
Amsterdam, The Netherlands
Course organisers
Prof. U. Beuers, Amsterdam, The Netherlands
Prof. P.L.M. Jansen, Amsterdam, The Netherlands

Cholestasis is an impairment of bile formation at the level of the hepatocyte and/or the biliary tree. Features of cholestasis dominate chronic cholestatic liver diseases and extrahepatic bile duct obstruction but can also be observed as a form of organ failure in a severely ill patient with a hitherto normal liver. Cholestasis is often seen in drug-induced liver injury. In children, cholestasis may hint at a genetic defect of hepatic metabolism including bile acid synthesis, membrane transporter formation and function, or bile duct development.

Although patients with chronic cholestatic liver disease are best treated by expert adult and pediatric physicians, patients with cholestasis are regularly seen in the surgical and obstetric ward and the intensive and coronary care units. Therefore, non-expert doctors need to be educated on basic aspects of liver physiology. Cholestasis as a consequence of extrahepatic obstruction by a stone or tumor is often easily diagnosed. A more difficult situation arises when cholestasis occurs as a consequence of malfunction of one of the hepatic transport pumps secondary to overt or occult sepsis, drugs, pregnancy, cardiac failure or post-operative secretory failure.

Ursodeoxycholic acid has been unchallenged as drug for the treatment of primary biliary cirrhosis and less so for the treatment of primary sclerosing cholangitis. Currently, various nuclear receptor and bile acid receptor agonists are subject of randomized trials the outcomes of which are eagerly awaited. The emergence of these drugs will change the field dramatically as some not only are candidate drugs for the treatment of cholestatic liver disease but also for seemingly unrelated conditions as non-alcoholic steatohepatitis and diabetes mellitus. Thus, the hepatologist is becoming more and more a metabolic doctor. In order to capture these changes a thorough understanding of liver physiology is mandatory.

In this EASL School of Hepatology we would like to present and discuss new data on diagnosis and management of cholestasis and cholestatic liver disease.

Objectives of this School of Hepatology

After attending this school you will better understand and be able to explain the following conditions to your colleagues:

  • New issues on liver physiology including the function of membrane transporters, nuclear receptors, bile acid receptors, signal transduction pathways
  • Diagnosis and management of cholestatic liver disease and its extrahepatic manifestations with major impact on quality of life such as pruritus and fatigue
  • Mechanism of action, indication and adverse effects of the new nuclear receptor and bile acid receptor agonists
  • Diagnosis and management of intrahepatic cholestasis as a hepatic manifestation of extrahepatic conditions and diseases including pregnancy, sepsis-induced and postoperative secretory failure
  • Pediatric cholestatic liver diseases and their relevance for the adult hepatologist
  • Indication and interpretation of liver biopsy in cholestasis and cholestatic liver disease
  • Management of polycystic liver disease
  • Surgical and non-surgical treatment of cholangiocarcinoma

Application for the EASL Schools of Hepatology is free.

For selected applicants, EASL will cover transportation costs to attend the school and accommodation during the event (details will be provided individually once the selection process has been done).

Application is open to young fellows under the age of 35 and/or still in training.

Approximately 30 places are available for each school and priority is given to registered EASL members during the selection process.

EASL Schools of Hepatology cover diverse aspects in the field of hepatology.
The course is divided into a balanced blend of lectures on theoretical, practical and clinical case-based discussions presented during a residential course with limited attendance.

Each school allows time for:

  • Intense interaction
  • Time for personal discussion
  • Exchanges with a distinguished faculty

The schools contribute to the training of new generations of hepatologists and are a major element of our association. Aimed at young fellows enrolled in hepatology-oriented departments or more experienced clinicians who want to be exposed to the newest trends in hepatology.

The 'EASL Clinical School of Hepatology Course 22 : Cholestatic disorders' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS),

The 'EASL Clinical School of Hepatology Course 22 : Cholestatic disorders' is designated for a maximum of (or 'for up to') 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Abstract submission

EASL premium sponsors

Document to download